A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07227402
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Belzutifan — DRUG
    Administered orally QD
  • Zanzalintinib — DRUG
    Administered orally QD
  • Cabozantinib — DRUG
    Administered orally QD

Study Details

Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.

Key Dates

Start date
Nov 26, 2025
Status verified
Jun 2026
Primary completion
Feb 27, 2032
Completion
Feb 27, 2032

Study Design

Enrollment
904 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Belzutifan plus Zanzalintinib
    Participants will receive belzutifan orally once daily (QD) PLUS zanzalintinib orally QD until one of the reasons for discontinuation of study intervention are met.
  • Active Comparator: Cabozantinib
    Participants will receive cabozantinib orally QD until one of the reasons for discontinuation of study intervention are met.

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: Up to approximately 73 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Alaska Oncology and Hematology ( Site 0133)AnchorageAlaska99508
Study Coordinator
907-257-9851

Find similar trials in Anchorage, AK

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Alaska Oncology and Hematology· Anchorage, AK

Related Studies